Physician profile
Ali Asghar
NPI 1164494571
$1,681.33
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $729 · 2020: $426 · 2021: $198 · 2022: $154 · 2023: $112 · 2024: $62.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $174.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $409.45 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $174.37 | 2021-2022 | |
| Allergan, INC. | $166.10 | 2019-2020 | |
| Abbvie INC. | $165.00 | 2022-2024 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $152.80 | 2019-2024 | Abilify Maintena |
| Janssen Pharmaceuticals, INC | $151.84 | 2019-2023 | Invega Sustenna |
| Alkermes, INC. | $134.61 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $122.54 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $97.20 | 2019-2020 | |
| Lundbeck LLC | $45.13 | 2020 | |
| Shire North American Group INC | $36.11 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Asghar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.